5th Dec 2018 11:57
LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday that Norgine BV has launched the company's treatment for iron deficiency, Ferracru, in the UK.
In September 2018, Shield, a commercial stage pharmaceutical company, licensed Feraccru to Norgine BV in Europe, Australia and New Zealand.
Under the deal with Norgine, Shields was entitled to a GBP11.0 million upfront payment. The company will also be eligible to receive up to EUR4.5 million in short-term development milestones and up to EUR50 million in sales milestones upon the achievement of specified targets.
Shield Therapeutics shares were untraded at 34.00 pence each on Wednesday.
Related Shares:
Shield Thera